Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI Following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2018 May 8

PMID 29731779

Citations 3

Authors

Prativa Sahoo

Paul Frankel

Julie Ressler

Margarita Gutova

Alexander J Annala

Behnam Badie

Jana Portnow

Karen S Aboody

Massimo DApuzzo

Russell C Rockne

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to correlate T1-weighted dynamic contrast-enhanced MRI- (DCE-MRI-) derived perfusion parameters with overall survival of recurrent high-grade glioma patients who received neural stem cell- (NSC-) mediated enzyme/prodrug gene therapy.

Methods: A total of 12 patients were included in this retrospective study. All patients were enrolled in a first-in-human study (NCT01172964) of NSC-mediated therapy for recurrent high-grade glioma. DCE-MRI data from all patients were collected and analyzed at three time points: MRI#1-day 1 postsurgery/treatment, MRI#2- day 7 ± 3 posttreatment, and MRI#3-one-month follow-up. Plasma volume (), permeability (), and leakage () perfusion parameters were calculated by fitting a pharmacokinetic model to the DCE-MRI data. The contrast-enhancing (CE) volume was measured from the last dynamic phase acquired in the DCE sequence. Perfusion parameters and CE at each MRI time point were recorded along with their relative change between MRI#2 and MRI#3 (Δ). Cox regression was used to analyze patient survival.

Results: At MRI#1 and at MRI#3, none of the parameters showed a significant correlation with overall survival (OS). However, at MRI#2, CE and were significantly associated with OS ( < 0.05). The relative and from timepoint 2 to timepoint 3 (Δ and Δ) were each associated with a higher hazard ratio ( < 0.05). All parameters were highly correlated, resulting in a multivariate model for OS including only CE at MRI#2 and Δ, with an of 0.89.

Conclusion: The change in perfusion parameter values from 1 week to 1 month following NSC-mediated therapy combined with contrast-enhancing volume may be a useful biomarker to predict overall survival in patients with recurrent high-grade glioma.

Citing Articles

Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma.

Woodall R, Sahoo P, Cui Y, Chen B, Shiroishi M, Lavini C Neurooncol Adv. 2022; 3(1):vdab174.

PMID: 34988454 PMC: 8715899. DOI: 10.1093/noajnl/vdab174.

The adaptive transition of glioblastoma stem cells and its implications on treatments.

Wang Z, Zhang H, Xu S, Liu Z, Cheng Q Signal Transduct Target Ther. 2021; 6(1):124.

PMID: 33753720 PMC: 7985200. DOI: 10.1038/s41392-021-00491-w.

Quantitative pharmacokinetic analysis of high-temporal-resolution dynamic contrast-enhanced MRI to differentiate the normal-appearing pituitary gland from pituitary macroadenoma.

Kamimura K, Nakajo M, Yoneyama T, Bohara M, Nakanosono R, Fujio S Jpn J Radiol. 2020; 38(7):649-657.

PMID: 32162178 DOI: 10.1007/s11604-020-00942-4.

References

Jenkinson M, Bannister P, Brady M, Smith S . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002; 17(2):825-41. DOI: 10.1016/s1053-8119(02)91132-8. View

Demicheli R, Retsky M, Hrushesky W, Baum M, Gukas I . The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008; 19(11):1821-8. DOI: 10.1093/annonc/mdn386. View

Hilario A, Sepulveda J, Hernandez-Lain A, Salvador E, Koren L, Manneh R . Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab. Clin Transl Oncol. 2016; 19(1):51-57. DOI: 10.1007/s12094-016-1502-4. View

Sahoo P, Rathore R, Awasthi R, Roy B, Verma S, Rathore D . Subcompartmentalization of extracellular extravascular space (EES) into permeability and leaky space with local arterial input function (AIF) results in improved discrimination between high- and low-grade glioma using dynamic contrast-enhanced (DCE).... J Magn Reson Imaging. 2013; 38(3):677-88. DOI: 10.1002/jmri.24021. View

Bago J, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin A . Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nat Commun. 2016; 7:10593. PMC: 4740908. DOI: 10.1038/ncomms10593. View

Calamante F, Thomas D, Pell G, Wiersma J, Turner R . Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab. 1999; 19(7):701-35. DOI: 10.1097/00004647-199907000-00001. View

Schmainda K . Diffusion-weighted MRI as a biomarker for treatment response in glioma. CNS Oncol. 2013; 1(2):169-80. PMC: 3734866. DOI: 10.2217/cns.12.25. View

Awasthi R, Rathore R, Soni P, Sahoo P, Awasthi A, Husain N . Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers. Neuroradiology. 2011; 54(3):205-13. DOI: 10.1007/s00234-011-0874-y. View

Aboody K, Brown A, Rainov N, Bower K, Liu S, Yang W . Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000; 97(23):12846-51. PMC: 18852. DOI: 10.1073/pnas.97.23.12846. View

10.

Hatzoglou V, Yang T, Omuro A, Gavrilovic I, Ulaner G, Rubel J . A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro Oncol. 2015; 18(6):873-80. PMC: 4864262. DOI: 10.1093/neuonc/nov301. View

11.

Ulmer S, Braga T, Barker 2nd F, Lev M, Gonzalez R, Henson J . Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology. 2006; 67(9):1668-70. DOI: 10.1212/01.wnl.0000242894.21705.3c. View

12.

Jenkinson M, Smith S . A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001; 5(2):143-56. DOI: 10.1016/s1361-8415(01)00036-6. View

13.

Haris M, Husain N, Singh A, Husain M, Srivastava S, Srivastava C . Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma. J Comput Assist Tomogr. 2009; 32(6):955-65. DOI: 10.1097/RCT.0b013e31816200d1. View

14.

Bag A, Cezayirli P, Davenport J, Gaddikeri S, Fathallah-Shaykh H, Cantor A . Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. J Neurooncol. 2014; 120(2):361-70. PMC: 4206596. DOI: 10.1007/s11060-014-1560-9. View

15.

Liberman G, Louzoun Y, Ben Bashat D . T₁ mapping using variable flip angle SPGR data with flip angle correction. J Magn Reson Imaging. 2014; 40(1):171-80. DOI: 10.1002/jmri.24373. View

16.

Jain K, Sahoo P, Tyagi R, Mehta A, Patir R, Vaishya S . Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI. Clin Radiol. 2015; 70(10):1128-35. DOI: 10.1016/j.crad.2015.06.076. View

17.

Aboody K, Najbauer J, Metz M, DApuzzo M, Gutova M, Annala A . Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med. 2013; 5(184):184ra59. PMC: 3864887. DOI: 10.1126/scitranslmed.3005365. View

18.

Johnson D, Patrick ONeill B . Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2011; 107(2):359-64. DOI: 10.1007/s11060-011-0749-4. View

19.

Portnow J, Synold T, Badie B, Tirughana R, Lacey S, DApuzzo M . Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients. Clin Cancer Res. 2016; 23(12):2951-2960. PMC: 8843778. DOI: 10.1158/1078-0432.CCR-16-1518. View

20.

Chen F, Ni Y . Magnetic resonance diffusion-perfusion mismatch in acute ischemic stroke: An update. World J Radiol. 2012; 4(3):63-74. PMC: 3314930. DOI: 10.4329/wjr.v4.i3.63. View